Howe Jill Ann 4

What Happened
Jill Ann Howe, Chief Financial Officer of Lineage Cell Therapeutics (LCTX), was granted 1,050,000 derivative securities (reported as an acquisition — code A) on March 5, 2026. The filing shows an acquisition price of $0.00 per unit (derivative award); the instruments are subject to a time-based vesting schedule described in the filing. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely under the 2-business-day rule).
• Security and amount: 1,050,000 derivative securities (grant). Reported price: $0.00 per unit.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnote (vesting): One quarter vests on March 5, 2027; the remaining 75% vests in 36 monthly installments thereafter, contingent on continuous employment.
• Transaction type: Award/Grant of derivative securities (options per footnote), not an immediate sale or exercise.

Context
This is a standard executive compensation award intended to align management incentives with long-term performance; it does not represent an immediate purchase or sale of underlying shares. Because the award vests over time, its value to the insider depends on continued employment and future company performance.